FibroBiologics (FBLG) Current Deferred Revenue (2024)
FibroBiologics (FBLG) posted quarterly Current Deferred Revenue of $241000.0 for Q3 2024, down 83.93% on a QoQ basis from $1.5 million in Q2 2024.
FibroBiologics (FBLG) Current Deferred Revenue (2024) Analysis & Trends
FibroBiologics has reported Current Deferred Revenue for 1 years, with the latest figure at $241000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 1.50 Mn |